195877-59-9

Upstream product

• 67-56-1 methanol 
• 127095-92-5 N-tert-butoxycarbonyl-D-cyclohexylalanine 
• 74-88-4 methyl iodide 

Downstream Products

• 769891-92-1 (R)-2-Amino-3-cyclohexyl-propionic acid methyl ester 
• 190904-17-7 N-(tert-butyloxycarbonylmethyl)-D-Cha-OMe 
• 190904-21-3 (2R)-2-[(tert-butoxycarbonyl)(2-tert-butoxy-2-oxoethyl)amino]-3-cyclohexylpropanoic acid 
• 190904-19-9 N-(tert-butyloxycarbonylmethyl)-N-Boc-D-Cha-OMe 
• 190904-25-7 {[(R)-2-(tert-Butoxycarbonyl-tert-butoxycarbonylmethyl-amino)-3-cyclohexyl-propionyl]-cyclopentyl-amino}-acetic acid 
• 190904-23-5 {tert-Butoxycarbonyl-[(R)-2-cyclohexyl-1-(cyclopentyl-methoxycarbonylmethyl-carbamoyl)-ethyl]-amino}-acetic acid tert-butyl ester 
• 194985-18-7 C₃₆H₆₂N₆O₉ 

Relevant academic research and scientific papers

Novel acylguanidine containing thrombin inhibitors with reduced basicity at the P1 moiety

Replacement of the noragmatine group in thrombin inhibitors with a β- alanyl-guanidine group resulted in a nearly equipotent and more selective compound 8 despite the fact that the pK(a) of this P1 moiety is five orders of magnitude lower. Furt

CARBOCYCLIC PROLINAMIDE DERIVATIVES

This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk